[Skip to Content]
[Skip to Content Landing]
January 14, 1911


JAMA. 1911;LVI(2):118-120. doi:10.1001/jama.1911.02560020034013

Indications at present are very strong that we are on the verge of a period of indiscriminate and reckless use of Ehrlich's new remedy, 606, or salvarsan, as it is known commercially, that will result in disappointment in that valuable remedy and—what is more important— in damage to many syphilitic patients, chiefly, let us hope, from neglect of established measures of treatment. Indeed, it will be very fortunate if we do not have another therapeutic fiasco, like that following the announcement of Koch's tuberculin, in which a valuable remedy failed to come up to first expectations, and thereby caused disappointment from which it did not recover for ten years. For in the excitement over 606 we are apparently remembering only that it was introduced to cure syphilis, and are therefore assuming that it will cure it, and are not taking heed of the fact that experience already is showing that

First Page Preview View Large
First page PDF preview
First page PDF preview